Lupus Erythematosus, Discoid Clinical Trial
Official title:
Efficacy of 595 nm Pulsed-dye Laser as an Adjunctive Treatment of Discoid Lupus Erythematosus, A Randomized, Patient/Assessor Blinded Placebo Control Trial
forty DLE lesions from patients will be recruited in the study. The lesions on one side of the body were block-randomized into the treatment group and the other side served as a control. The patients can continue their systemic treatments and the PDL is designed to be used as an adjunctive treatment. Treatments with the PDL will be delivered in the treatment group every 4 weeks for 4 consecutive months while the lesions in the control group received a sham. The patients will be evaluated at baseline (week 0), week 4, 8, 12, and at follow-up period of 4, 12 weeks after the final treatment (week 16, 24). Erythema index (EI), Texture index (TI) will be obtained and digital photographs will be taken and modified Cutaneous Lupus Erythematosus Disease Area and Severity Index (mCLASI) will be assessed in every visit. The digital photographs will later be evaluated by 3-blinded dermatologists. Moreover, side effects and patients' satisfaction score will also be recorded.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02034344 -
A Study of Skin and Systemic Biomarkers In Patients With Active Cutaneous Lupus Erythematosus And In Healthy Volunteers
|
Phase 0 | |
Completed |
NCT01858792 -
A Pooled Analysis of the HGS1006-C1056 (BLISS-52) and HGS1006-C1057 (BLISS-76) Studies
|
N/A | |
Withdrawn |
NCT00222183 -
Cutaneous Lupus Erythematosus and Elidel
|
N/A | |
Active, not recruiting |
NCT04857034 -
A Study to Evaluate Efficacy and Safety of Deucravacitinib in Participants With Active Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE)
|
Phase 2 | |
Completed |
NCT01845740 -
Phase Ib Study of SC Milatuzumab in SLE
|
Phase 1 | |
Completed |
NCT02656082 -
Targeted Therapy Using Intradermal Injection of Etanercept for Remission Induction in Discoid Lupus Erythematosus
|
Phase 2 | |
Terminated |
NCT02428309 -
Autologous Polyclonal Tregs for Lupus
|
Phase 1 | |
Completed |
NCT01597050 -
Safety and Efficacy of Topical R333 in Patients With Discoid Lupus Erythematosus (DLE) and Systemic Lupus Erythematosus (SLE) Lesions
|
Phase 2 | |
Completed |
NCT01923415 -
A Non-drug Study Profiling Cutaneous Lupus
|
Phase 0 |